PSTX חוב לטווח קצר של החברה Poseida Corp
The price trend for Poseida Therapeutics (PSTX) shown in this chart reflects the dynamics of an asset valued at 0.00. Poseida Therapeutics is developing non-viral gene delivery systems via piggyBac technology to reduce production costs. Monetization is driven by DNA modification patents and deals with industry behemoths. However, high laboratory expenses are currently absorbing primary payouts, limiting the business's current profitability.
פילוחים אנליטיים ודוחות נתונים של חברת Poseida Corp (PSTX)
A conservative investor assesses the fundamental stability of Poseida Therapeutics (PSTX) by monitoring liquidity and the ability to service current liabilities. This metric aggregates all debts with a maturity of up to one year, and an analysis of short-term balance sheet liabilities allows for an assessment of the company's financial cushion amid geopolitical risks affecting raw material costs and the conduct of international clinical trials.